NAS
ALNY icon

Nykredit A/S’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nykredit A/S’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
+43,641
New +$13.2M 0.05% 282

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nykredit A/S's ALNY Position: Q2 2026 in Review

Nykredit A/S opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 43,641 shares worth $13.1M. The stake represents 0.05% of the portfolio and ranks #282 among its holdings.

793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Nykredit A/S held 43,641 shares of Alnylam Pharmaceuticals worth $13.1M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.05% of Nykredit A/S's portfolio in Q2 2026, its #282 holding.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.